Nov.20 -- Roche Holding AG Chief Executive Officer Severin Schwan said the firm will be able to make the first deliveries of its Covid-19 antibody treatments in the first quarter of next year. The Swiss drug company has filed for emergency authorization for an antibody cocktail it’s working on with U.S. biotech Regeneron Pharmaceuticals Inc. and that could be granted “very soon,” Schwan said on "Bloomberg Surveillance."
